Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735447 | 0.96 | TLR8 (0.40) | TLR8CNR1CNR2BDKRB2TYR | |
| SCHEMBL6736893 | 0.96 | TLR8 (0.39) | TLR8BDKRB2TYRSKP2HTR1A | |
| SCHEMBL6741609 | 0.94 | SKP2 (0.36) | TLR8BDKRB2SKP2ALOX5HTR1A | |
| SCHEMBL6732184 | 0.93 | TLR8 (0.42) | TLR8BDKRB2SKP2HTR1A | |
| SCHEMBL6731773 | 0.93 | TLR8 (0.42) | TLR8BDKRB2SKP2HTR1A | |
| SCHEMBL6734816 | 0.92 | TLR8 (0.43) | TLR8BDKRB2HTR1A | |
| SCHEMBL6736312 | 0.92 | CYP1A2 (0.40) | TLR8BDKRB2TYRPTPN1BCHE | |
| SCHEMBL6731904 | 0.90 | TLR8 (0.40) | TLR8BDKRB2HTR1A | |
| SCHEMBL6736335 | 0.89 | SKP2 (0.36) | TLR8BDKRB2SKP2HTR1ABCHE | |
| SCHEMBL6736746 | 0.89 | CNR1 (0.37) | CNR1CNR2ALOX5NCEH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6682785-B2 | A FLUOROANTHRACENE COMPOUNDS; HEAT RESISTANCE, RADIATION RESISTANCE, PHOTOSTABILITY | CLARIANT FINANCE (BVI) LIMITED (VG) | 2004-01-27 | — | — | US | disclosed |
| US-20030118749-A1 | A fluoroanthracene compounds; heat resistance, radiation resistance, photostability | CLARIANT INTERNATIONAL LTD. | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118749-A1 | A fluoroanthracene compounds; heat resistance, radiation resistance, photostability | HSF1, ABCC1, FLNA | TLR8 3408/4885CNR1 2742/4885CNR2 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.